Skip to main content
. Author manuscript; available in PMC: 2014 May 6.
Published in final edited form as: Leukemia. 2013 Jun 14;27(9):1832–1840. doi: 10.1038/leu.2013.180

Figure 3. Activation of IL-8 and JMJD3 gene expression by TLR2 signaling in primary BM CD34+ cells.

Figure 3

(a) Logarithmic representation of Q-RTPCR result of IL-8 gene in MDS and control CD34+ cells. (b) Q-RTPCR analysis of IL-8 and JMJD3 RNA expression in cultured BM CD34+ cells after treatment with TLR2 agonist MALP2 and PAM3CSK4. (c) Q-RTPCR analysis of IL-8 RNA expression in OCI-AML3 cells after JMJD3 knock-down. (d) H3K4me3 CHIP-PCR analysis of IL-8 promoter in the OCI-AML3 cells after JMJD3 knock-down. (e) H3K27me3 CHIP-PCR analysis of IL-8 promoter in OCI- AML3 cells after JMJD3 knock-down.